234 filings
Page 4 of 12
8-K
3wkeby4m7 v1l5t
21 Jun 19
Departure of Directors or Certain Officers
4:06pm
8-K
kfeq fbrhi
18 Jun 19
Casi Pharmaceuticals Acquires Worldwide Rights to Commercialize ANTI-CD19 T-cell Therapy
4:01pm
8-K
sdllg5zicpa6ypl5i
15 May 19
Casi Pharmaceuticals Announces First Quarter 2019
9:00am
8-K
oya2fp4k yhvm
17 Apr 19
Entry into a Material Definitive Agreement
4:03pm
8-K
wyby97nq 3w1
5 Apr 19
Casi Pharmaceuticals Announces the Appointment of Wei-wu He, PH.D., Executive Chairman, to the Role of Chief Executive Officer
4:31pm
8-K
yx28r2 9579
29 Mar 19
Full Year 2018 Financial Results and Business Results
9:00am
8-K
3cw01hrauur hthv78bq
13 Mar 19
Casi Pharmaceuticals Announces Exclusive Distribution Partner for Melphalan Hydrochloride for Injection (Evomela®) In China
5:18pm
8-K
9vdzlc2o8jztq1
19 Feb 19
Other Events
5:23pm
8-K
li2orahpg66 nv
29 Jan 19
Changes in Registrant's Certifying Accountant
4:46pm
8-K
0pak21501 wji3hauvra
6 Dec 18
Casi Pharmaceuticals Announces China Market Approval
4:30pm
8-K
wa2 qiouh
20 Nov 18
Entry into a Material Definitive Agreement
5:07pm
8-K
pgnvkmw zsy
14 Nov 18
Casi Pharmaceuticals Announces Third Quarter and First Nine Months
9:02am
8-K/A
ydem anst8egr5mth
24 Oct 18
Departure of Directors or Certain Officers
5:02pm
8-K
busdfkyg5gpl3akzh65
24 Oct 18
Casi Pharmaceuticals Acquires HBV Anda
4:57pm
8-K
964sy3yy5r
28 Sep 18
Casi Pharmaceuticals Announces Appointment of Chief Financial Officer
8:13pm
8-K
zjx5z2tf2r8 th
27 Sep 18
Changes in Registrant's Certifying Accountant
8:13pm
8-K
c86x xg45n27
14 Sep 18
Casi Pharmaceuticals Announces $48.5 Million Private Placement
12:00am
8-K
mmvxmm9
14 Aug 18
Casi Pharmaceuticals Announces Second Quarter and First Half 2018 Financial and Business Results
9:00am
8-K
0dcwgcamjnydi xt4pb
11 Jun 18
Departure of Directors or Certain Officers
5:17pm
8-K
8vzz9gl 5euq
15 May 18
Casi Pharmaceuticals Announces First Quarter 2018
9:00am